Related Experiment Videos
[Role of peptide leukotrienes in monocrotaline-induced lung disease]
Abstract:
Monocrotaline (MCT) causes lung inflammation and right ventricular hypertrophy associated with lung vascular thickening in rats. We hypothesized that peptide leukotrienes play a role in MCT-induced lung disease, and examined the effect of ONO 1078, a specific antagonist of LTC4, D4 and E4 receptors on MCT-induced right ventricular hypertrophy and on lung vascular thickening. Next, we measured leukotriene C4 (LTC4) levels in the lung tissue of MCT-treated rats. Within 3 weeks after the injection MCT had caused an increase in the ratio of right ventricular weight to left ventricle+septum weight (RV/(LV+S)) and an increase in media wall thickness of the muscular arteries of the lung. In rats given both ONO 1078 and MCT, these changes were significantly less severe than in rats given MCT only. The LTC4 levels in MCT-treated rats were significantly higher than in saline-treated control rats. These results indicate that this antagonist of peptide leukotriene receptors inhibits right ventricular hypertrophy induced by MCT, and suggest a role for peptide leukotrienes in the inflammatory process that contributes to lung vascular remodeling in MCT-treated rats.
Insights
Peptide leukotrienes contribute to lung disease caused by monocrotaline (MCT). Blocking their receptors with ONO 1078 reduced right ventricular hypertrophy and lung vascular thickening in rats, indicating a therapeutic target.
Area of Science:
- Pulmonary Medicine
- Pharmacology
- Cardiovascular Research
Background:
- Monocrotaline (MCT) induces lung inflammation, right ventricular hypertrophy, and pulmonary vascular remodeling in rats.
- Peptide leukotrienes are implicated in inflammatory processes contributing to lung disease.
Purpose of the Study:
- To investigate the role of peptide leukotrienes in MCT-induced lung disease.
- To evaluate the efficacy of ONO 1078, a leukotriene receptor antagonist, in mitigating MCT-induced pathology.
Main Methods:
- Rats were treated with MCT alone or in combination with ONO 1078.
- Right ventricular hypertrophy was assessed by the RV/(LV+S) weight ratio.
- Lung vascular thickening was measured morphometrically.
- Lung tissue leukotriene C4 (LTC4) levels were quantified.
Main Results:
- MCT treatment led to significant right ventricular hypertrophy and increased pulmonary artery wall thickness.
- Co-administration of ONO 1078 significantly attenuated these MCT-induced changes.
- LTC4 levels were elevated in the lungs of MCT-treated rats compared to controls.
Conclusions:
- Peptide leukotriene receptor antagonism effectively inhibits MCT-induced right ventricular hypertrophy.
- These findings suggest that peptide leukotrienes play a crucial role in MCT-induced pulmonary vascular remodeling and inflammation.